PMDAsafety guidance72% confidence
[IBENTO][IBENTO]The report for the PMDA Asia office GMP Workshop Training 2026 has been posted.
Source: PMDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as opioid treatment pharma companies.
Regulatory Analysis
PMDA document relevant to the signal.
Supporting Context
- Therapeutic area
- Addiction · Opioids
- Sub-indication
- Pain
Related signal: University of Missouri-Columbia Launches Naloxone Training Initiative to Combat Opioid Overdoses